Biological Therapy in Treating Patients With Primary or Advanced Glioma

Paused · Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or advanced glioma. PURPOSE: Clinical trial to study the effectiveness of biological therapy with interleukin-2 and lymphokine-activated killer cells in treating patients who have primary, recurrent, or refractory malignant glioma.

Key facts

Study ID

NCT00003067

Run by

Weill Medical College of Cornell University

Starts

1997-07-01

Last updated by the study team

2009-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Staten Island University Hospital — Staten Island, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.